Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2012 - 2018)
Catalyst Pharmaceuticals' (CPRX) quarterly Current Deferred Revenue came in at $33408.0 in Q4 2018, up 39.14% YoY from $24011.0 in Q4 2017, and up 52.45% on a QoQ basis from $21914.0 in Q3 2018.
Powered by 
Analysis
Catalyst Pharmaceuticals (CPRX) Current Deferred Revenue (2012 - 2018) Analysis & Trends
Catalyst Pharmaceuticals (CPRX) has 7 years of Current Deferred Revenue data on file, last reported at $33408.0 in Q4 2018.
- Quarterly Current Deferred Revenue rose 39.14% year-over-year to $33408.0 in Q4 2018, while the trailing twelve-month figure through Dec 2018 was $33408.0 (up 39.14% YoY) and the FY2018 annual result came in at $33408.0, up 39.14% from the prior year.
- Current Deferred Revenue improved to $33408.0 in Q4 2018, from $21914.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $33408.0 in Q4 2018 to a low of $3254.0 in Q1 2014.
- A 5-year average of $16181.7 and a median of $18094.0 in 2016 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2015 — Current Deferred Revenue soared 335.14% — and 2018, when it decreased 2.27%.
- Tracing CPRX's Current Deferred Revenue over 5 years: stood at $4158.0 in 2014, then soared by 335.14% to $18093.0 in 2015, then grew by 0.01% to $18094.0 in 2016, then surged by 32.7% to $24011.0 in 2017, then jumped by 39.14% to $33408.0 in 2018.
- The last three Current Deferred Revenue figures came in at $33408.0 (Q4 2018), $21914.0 (Q3 2018), and $27184.0 (Q2 2018), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 33,408.00 |
| Sep 30, 2018 | 21,914.00 |
| Jun 30, 2018 | 27,184.00 |
| Mar 31, 2018 | 25,597.00 |
| Dec 31, 2017 | 24,011.00 |
| Sep 30, 2017 | 22,424.00 |
| Jun 30, 2017 | 20,867.00 |
| Mar 31, 2017 | 19,328.00 |
| Dec 31, 2016 | 18,094.00 |
| Dec 31, 2015 | 18,093.00 |
| Sep 30, 2015 | 18,093.00 |
| Jun 30, 2015 | 5,702.00 |
| Mar 31, 2015 | 4,930.00 |
| Dec 31, 2014 | 4,158.00 |
| Sep 30, 2014 | 4,270.00 |
| Jun 30, 2014 | 3,762.00 |
| Mar 31, 2014 | 3,254.00 |
| Dec 31, 2013 | 2,746.00 |
| Sep 30, 2013 | 2,245.00 |
| Jun 30, 2013 | 1,752.00 |